India is significantly boosting its strategic efforts to eliminate cervical cancer, a leading cause of cancer mortality among women in the country. The comprehensive plan emphasizes two key pillars: enhancing Human Papillomavirus (HPV) vaccination coverage and introducing high-performance HPV DNA testing, including self-sampling options. These initiatives align with the World Health Organization's (WHO) '90-70-90' global strategy, which aims for 90% HPV vaccination coverage in girls by age 15, 70% screening coverage for women, and 90% treatment access for precancerous lesions or cancer by 2030. Momentum for this drive has notably increased with the Indian government's commitment, highlighted by the Finance Minister's announcement in the February 2024 Interim Budget to include HPV vaccination for girls aged 9-14 years in the Universal Immunization Programme (UIP). This move is complemented by the launch of India's first indigenously developed quadrivalent HPV vaccine, 'CERVAVAC,' in 2022-2023, making vaccines more accessible and affordable. Plans are underway for school-based vaccination drives and community outreach programs to ensure widespread reach and address vaccine hesitancy. A recent national summit held at AIIMS in January 2026 underscored the collective resolve of government bodies and cancer institutions to translate these policies into tangible actions. The discussions focused on system-wide alignment and ensuring equitable access to high-quality care, including the crucial transition to high-performance HPV DNA testing, which allows for convenient self-sampling. While India faces a substantial cervical cancer burden, accounting for over 65% of cases in the Southeast Asia Region and more than one-fifth of global cases and deaths, these strategic interventions offer a hopeful path toward elimination, potentially saving millions of lives by 2120 if WHO targets are met.